WO2005046611A2 - Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease - Google Patents
Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease Download PDFInfo
- Publication number
- WO2005046611A2 WO2005046611A2 PCT/US2004/037703 US2004037703W WO2005046611A2 WO 2005046611 A2 WO2005046611 A2 WO 2005046611A2 US 2004037703 W US2004037703 W US 2004037703W WO 2005046611 A2 WO2005046611 A2 WO 2005046611A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- unsubstituted
- substituted
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- the present invention provides novel glucoirnidazole (GIZ) and polyhydroxycyclohexenyl amine (PHCA) derivatives having a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof.
- the present invention further provides a method for treating individuals having Gaudier disease by administering the novel GIZ or PHCA derivatives as "active-site specific chaperones" for the mutant glucocerebrosidase associated with the disease.
- Protein Folding Proteins are synthesized in the cytoplasm, and the newly synthesized proteins are secreted into the lumen of the endoplasmic reticulum (ER) in a largely unfolded state.
- ER endoplasmic reticulum
- protein folding is governed by the principle of self assembly. Newly synthesized polypeptides fold into their native conformation based on their amino acid sequences (Anfinsen et al., Adv. Protein Chem. 1975; 29:205-300).
- protein folding is complicated, because the combination of ambient temperature and high protein concentration stimulates the process of aggregation, in which amino acids normally buried in the hydrophobic core interact with then neighbors non-specifically.
- molecular chaperones which prevent nascent polypeptide chains from aggregating, and bind to unfolded protein such that the protein refolds in the native conformation.
- Molecular chaperones are present in virtually all types of cells and in most cellular compartments. Some are involved in the transport of proteins and permit cells to survive under stresses such as heat shock and glucose starvation.
- molecular chaperones (Gething et al., Nature 1992; 355:33-45; Caplan, Trends Cell. Biol. 1999; 9:262-268; Lin et al. , Mol. Biol. Cell.
- Bip immunoglobulin heavy-chain binding protein
- This process serves as a "quality control" system in the ER, ensuring that only those properly folded and assembled proteins are transported out of the ER for further maturation, and improperly folded proteins are retained for subsequent degradation (Hurtley et al., Aram. Rev. Cell. Biol. 1989; 5:277-307).
- Certain missense mutations result in amino acid substitutions that alter the native and proper folding of the protein. To correct these misfoldings, investigations have attempted to use various molecules as artificial chaperones.
- the enzyme would be retarded in the normal transport pathway from the ER to the Golgi apparatus and subjected to rapid degradation. If a mutant enzyme could be efficiently transported to the lysosomes, it may retain normal or near normal kinetic properties and would remain active, because the mutant enzyme is sufficiently stable below pH 5.0. The goal, therefore, was to induce the mutant enzyme to adjust the proper conformation in the ER.
- a compound that can induce a stable molecular conformation of the enzyme could serve as an "active- site specific chaperone" (ASSC) or "pharmacological chaperone" to stabilize the mutant enzyme in a proper conformation for transport to the lysosomes.
- ASSC active- site specific chaperone
- pharmacological chaperone to stabilize the mutant enzyme in a proper conformation for transport to the lysosomes.
- Potent Inhibitors of ⁇ -glucocerebrosidase ⁇ -Glucocerebrosidase is a lysosomal hydrolase that catalyzes the hydrolytic cleavage of glucose from glucosylceramide (Brady et al, Biochem. Biophys. Res. Commun. 1965; 18:221-225).
- glucosylceramide a normal intermediate in the catabolism of globoside and gangliosides, in lysosomes of macrophages, leading to Gaucher disease, the most common lysosomal storage disorder (Beutler et al., in The Metabolic and Molecular Bases of Inherited Disease, 8th ed., McGraw-Hill, New York 2001, 3635-3668). Details regarding the disease and therapeutic treatment will be described below.
- ⁇ -glycosidases The catalytic mechanism of ⁇ -glycosidases is believed to proceed via a covalent glycosyl-enzyme intermediate with a positive charge generated at the anomeric position (Ichikawa et al., J. Am. Chem. Soc. 1998; 120:3007-3018; Heightman et al., 1999; Angew. Chem. Int. Ed. 1999; 38:750-770).
- Ichikawa et al. have designed a class of potent inhibitors for ⁇ -glycosidases, 1-N-iminosugars in which a nitrogen atom is at the anomeric position of a monosaccharide (Structure 1A, Isofagomine or hydroxypiperidine).
- D-glucose-type 1- N-iminosugar (isofagomine, or hydroxypiperidine 1) has been shown to be a potent inhibitor of GCase (U.S. Patent 6,583,158 to Fan et al.).
- N-alkyl derivatives of 1- deoxynojirimycin (DNJ) are also potent inhibitors of GCase, particularly those have longer alkyl group (greater than Ce alkyl chain), although DNJ itself and those N- alkyl DNJ with shorter chains are not inhibitory (Structure IB, N-nonyl 1- deoxynojirimycin) (U.S. Patent 6,583,158).
- GCase may contain two substrate binding sites in the catalytic domain: one which recognizes the glucosyl residue; the other which recognizes the ceramide moiety (Structure IC, 6-nonyl hydroxypiperidine, RD-1: recognition domain 1; RD-2: recognition domain 2.).
- isofagomine (IFG) and N-octyl valienamine were found to be the most potent inhibitors of GCase, with ICso values of approximately 50 nM, or 300 nM, respectively (PCT/JP02/08882 to Ogawa et al; Ogawa et al., Bioorg. Med. Chem. Lett. 1996; 6:929-932).
- tetrahydroimidazopyridines or glucoimidazole (GIZ) derivatives were also found to be potent inhibitors of ⁇ -glucosidases (Panday et al., Helvetica Chimica Acta 2000; 83:58-75). Although the inhibitors described by Panday were potent, they lack specificity for GCase. Thus, there remains a need in the art to design or identify specific competitive inhibitors of enzymes, and evaluate them for their ability to act as chaperones for the corresponding mutant enzymes that are associated with numerous LSDs, particularly inhibitors of GCase associated with Gaucher disease, and other disorders resulting from misfolded proteins.
- the present invention provides a compound of the Formula I:
- the present invention also provides a compound of the Formula II:
- the present invention also provides salts, esters and prodrugs of the compounds of Formula II. Additionally, the present invention described methods of synthesizing compounds according to Formula I. The present invention also provides salts, esters and prodrugs of the compounds of Formula I and Formula II. The present invention further provides a method of enhancing in a mammalian cell the activity of GCase by contacting the cell with a compound of Formula I or Formula II in an amount effective to enhance the activity of GCase, i.e. , a non-inhibitory amount.
- the present invention also provide a method of stabilizing in mammalian cell the GCase by contacting the cell with a compound of Formula I or Formula II in an amount effective to stabilize the GCase.
- the present invention also provides compositions comprising a compound of Formula I and Formula II and a pharmaceutically acceptable carrier. Also provided is a method for treating Gaucher disease by administering to an individual in need of such treatment a pharmaceutical composition comprising a compound of Formula I or Formula II in an amount effective to enhance the activity of GCase.
- the present invention provides a method of inhibiting GCase in a mammalian cell when used at an inhibitory concentrations, by contacting the cell with a compound of Formula I or Formula II.
- the present invention provides a method of inhibiting GCase in vitro, when used at an inhibitory concentrations, by contacting the cell with a compound of Formula I or Formula II.
- the present invention provides a method of inhibiting ⁇ -glucosidases in a mammalian cell when used at an inhibitory concentrations, by contacting the cell with an inhibitory concentration of a compound of Formula I or Formula II.
- the present invention provides a method of inhibiting ⁇ -glucosidase in vitro, when used at an inhibitory concentrations, by contacting the cell with a compound of Formula I or Formula II.
- Figure 1 Structures of GCase-specific compounds, (a) DNJ, 1- deoxynojirimycin; (b) IFG, isofagomine; (c) GIZ, glucoimidazole; (d) 2-PE-GIZ, 2- phenylethyl glucoimidazole; (e) 2-octyl GIZ, 2-octyl glucoimidazole, and (f) 2- DMB GIZ, 2-dimethylbutyl GIZ. Figure 2. Synthesis of glucoimidazole derivatives.
- the enzyme activity was performed as indicated in the text.
- GIZ glucoimidazole
- o 2-phenylethyl glucoimidazole
- A 2-octyl glucoimidazole.
- the present invention provides the design and synthesis of a novel class of potent competitive inhibitors of GCase, glucimidazole (GIZ), and polyhydroxy- cyclohexyl amine (PHCA) derivatives of glucose, and demonstrates their ability to increase the residual enzyme activity in fibroblasts from Gaucher patients with N370S mutation.
- Gaucher Disease Gaucher disease is a lysosomal storage disorder resulting from the deficient activity of /5-glucocerebrosidase (hereinafter referred to as GCase) and the accumulation of its undegraded substrate, glucosylceramide (glucocerebroside), a normal intermediate in the catabolism of globoside and gangliosides (Beutler et al. , The Metabolic and Molecular Bases of Inherited Disease, 8th ed. 2001; Scriver, C. R., Beaudet, A. L., Sly, W. S. and Valle, D., ed.) pp. 3635-3668, McGraw-Hill, New York).
- GCase /5-glucocerebrosidase
- the deficient activity of GCase is caused by mutations in the GCase gene, resulting in misfolding and subsequent degradation of the gene product in the ER.
- three clinical phenotypes are generally distinguished: (i) the non-neuronopathic variant (type 1, or adult form); (ii) the acute neuronopathic variant (type 2, or infantile form); and (iii) the subacute neuronopathic variant (type 3 or juvenile form).
- Type 1 Gaucher disease characterized by hepatosplenomegaly, secondary hypersplenism, and skeletal involvement is the most prevalent form and the severity and clinical course of this variant is particularly heterogeneous, ranging from early onset to no clinical manifestations (Grabowski, Gaucher disease: Enzymology, genetics, and treatment.1993, Plenum Press, New York).
- patients with the neurologic forms are rare.
- the correlation of clinical severity and genotypes indicates that mild mutations presenting residual enzyme activity often result in type 1 disease, whereas severe or null mutations cause type 3 or type 2 disease.
- Gaucher patients have been found from all regions of the world.
- the disease is most common in the Ashkenazi Jewish population, where the frequency of Gaucher disease-causing alleles is approximately 0.0343 (Beutler et al., supra). The incidence is estimated as 1:4,000 (Mathoth et al., Am JMed Genet. 1987; 27: 561-5). Approximately 97% of GCase mutations in Ashkenazi Jews and 75 % of the GCase mutations in non- Jewish populations can be detected by screening for the five most common mutations.
- the N370S mutation which results in exclusively type 1 Gaucher disease is the most common mutation and is reported to be present in about 6% of the Ashkenazi Jewish population (Beutler et al., Blood 1992; 79: 1662-6).
- An insertion of a G at nucleotide position 84 of the cDNA is the second common Jewish mutation. It is found in approximately 0.6% of the Jewish population.
- GCase cDNA is about 2 kb in length, and active enzyme can be produced from in vivo translation of the cDNA in a variety of eukaryotic cells, including COS cells and insect cells infected with baculovirus (Grabowski et al., Enzyme 1989; 41: 131-42).
- Human GCase is a homomeric glycoprotein.
- the mature polypeptide is 497 amino acids with a calculated molecular mass of 55,575.
- the glycosylated enzyme from placenta has a molecular weight of about 65 kD.
- Saposin C activates GCase in vitro in the presence of negatively charged phospholipids.
- ASSC active site specific chaperone
- ASSC uses low concentrations of potent enzyme inhibitors, which are specific for the mutant (or wild type) enzyme, to enhance the folding and activity of the mutant proteins in patients with LSDs.
- the active site inhibitors used in ASSC are specific for the disease-causing enzyme, the therapy is targeted to a single protein and a particular metabolic pathway, unlike SRT which inhibits an entire synthetic pathway.
- SRT the small molecule inhibitors for ASSC have the potential of crossing the blood brain barrier and therefore could be used to treat neurological LSD forms.
- the present invention contemplates administering an inhibitory amount of the ⁇ - glucosidase inhibitors to animals to mimic the Gaucher disease phenotype.
- alkyl refers to a straight or branched C1-C20 hydrocarbon group consisting solely of carbon and hydrogen atoms, containing no unsaturation, and which is attached to the rest of the molecule by a single bond, e.g. , methyl, ethyl, «-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl).
- the alky Is used herein are preferably Ci - Cs alkyls.
- alkenyl refers to a C2-C20 aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be a straight or branched chain, e.g. , ethenyl, 1-propenyl, 2-pro ⁇ enyl (allyl), iso-propenyl, 2-methyl-l- propenyl, 1-butenyl, 2-butenyl.
- alkynyl refers to a C2-C20 straight or branched chain hydrocarbon radicals having at least one carbon-carbon triple bond, e.g. ethynyl, propynyl, butnyl.
- cycloalkyl denotes an saturated, non-aromatic mono- or multicyclic hydrocarbon ring system such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
- multicyclic cycloalkyl groups include perhydronapththyl, adamantyl and norbornyl groups bridged cyclic group or sprirobicyclic groups, e.g. , spiro (4,4) non-2-yl.
- cycloalkenyl an unsaturated, non-aromatic mono- or multicyclic hydrocarbon ring system containing 3 to about 14 carbon atoms, system such as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl.
- cycloalkalkyl refers to a cycloalkyl as defined above directly attached to an alkyl group as defined above, that results in the creation of a stable structure such as cyclopropylmethyl, cyclobutylethyl, cyclopentylethyl.
- aryl refers to aromatic radicals having in the range of about 6 to about 14 carbon atoms such as phenyl, naphthyl, tetrahydronapthyl, indanyl, biphenyl.
- arylalkyl refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g. , -CH2C6H5, and -C2H4C6H5.
- heterocyclic ring or “heterocyclyl” refer to a stable 3- to 15- membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, phosphorus, oxygen and sulfur.
- the heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states.
- the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e. , heteroaromatic or heteroaryl aromatic).
- heterocyclic ring radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofurnyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pyridyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl, imidazolyl, tetrahydroisouinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2- oxopyrrolidin
- heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
- heteroarylalkyl refers to heteroaryl ring radical as defined above directly bonded to alkyl group.
- the heteroarylalkyl radical may be attached to the main structure at any carbon atom from alkyl group that results in the creation of a stable structure.
- heterocyclylalkyl refers to a heterocylic ring radical as defined above directly bonded to alkyl group.
- the heterocyclylalkyl radical may be attached to the main structure at carbon atom in the alkyl group that results in the creation of a stable structure.
- lipophilic refers to a functional residue capable of interacting with hydrophobic amino acid residues.
- liphophilic groups include but are not limited to C1-C12 substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl; substituted or unsubstituted cycloalkenyl; substituted or unsubstituted aryl; substituted or unsubstituted arylalkyl; substituted or unsubstituted heteroaryl; substituted or unsubstituted heterocyclic; substituted or unsubstituted heterocycloalkyl; and substituted or unsubstituted heteroarylalkyl.
- halogen refers to radicals of fluorine, chlorine, bromine and iodine.
- hydrochloride refers to protecting groups capable of removal by hydrogenating conditions, for example, benzyl and 4- methoxybenzyl.
- acid refers to Bronsted or Lewis acid such as sulfuric acid, hydrochloride or hydrochloride generated by reaction of acid chloride with alcohol.
- organic acid refers to organic to Bronsted or Lewis acid such as ⁇ -toluenesulfonic acid, camphor sulfonic acid.
- crown ether refers to large ring compounds containing several oxygen atoms in a regular pattern such as 12-crown-4, 15-crown-5, 18-crown-6, dicyclohexano- 18-crown-6.
- organometallic reagent refers to a compound that contains a bond between a carbon and a metal atom, such as organolithium, organozinc, organocopper, Grignard reagents.
- hydrolysis conditions refers to catalytic hydrogenolysis using catalyst such as, but not limited to, Pd(OH)2/C, Pd/C, Pt or Raney nickel in the presence of a hydrogen source.
- hydrolysis refers to a chemical reaction in which unsaturated bond between carbon atoms are reduced by attaching a hydrogen atom to each other using catalyst such as, but not limited to, Pd(OH)2/C, Pd/C, Pt or Raney nickel in the presence of a hydrogen source.
- reducing agent refers to an agent converting a functional group in a molecule from one oxidation state to lower one, such as LiAlH 4 , NaBH 4 , Zn(BH 4 )2, -BuzAlH and Li-s-BusH.
- leaving group refers to a group that can be substituted by nucleophilic reagent, such as TsO-, TfO-, MsO-, Cl, Br, I.
- N-protecting group refers to groups temporarily protecting amine or imine group to avoid further sites of reaction, such as, but not limited to, 4-methoxybenzyl, benzyl, tert-butyloxycarbonyl, benzyloxycarbonyl.
- O-protecting group refers to groups temporarily protecting an hydroxy to avoid further sites of reaction, such as, but not limited to, 4- methoxybenzyl, benzyl, and trimethylsilyl.
- base refers to organic Lewis base, such as pyridine, triethylamine , diisopropylethylamine .
- nucleophilic moiety and nucleophilic reagent refer to a reagent that forms a bond to its reaction partner (the electrophile) by donating both bonding electrons, such as metal salt of an alcohol, thiol, or 1-alkyne.
- a short flexible linker refers to linkers with linear length of about 6A to about 12A, preferably about 9A.
- ASSC active site specific chaperone
- ASSC refers to any molecule including but not limited to a protein, peptide, nucleic acid, carbohydrate, that specifically interacts reversibly with an active site of a protein and enhances formation of a stable molecular conformation.
- ASSC does not include endogenous general chaperones present in the ER of cells such as Bip, calnexin or calreticulin, or general, non-specific chemical chaperones such as deuterated water, DMSO, or TMAO.
- the term "active site” refers to the region of a protein that binds a substrate or binding partner and contributes the amino acid residues that directly participate in the making and breaking of chemical bonds. According to the present invention, the active site encompasses the catalytic domain of the GCase.
- wild-type activity refers to the normal physiological function of a GCase in a cell. Such functionality can be tested by any means known to establish functionality of a protein, specifically, an enzyme. Certain tests may evaluate attributes of a protein that may or may not correspond to its actual in vivo function, but nevertheless are aggregate surrogates of protein functionality, and wild-type behavior in such tests is an acceptable consequence of the protein folding rescue techniques of the invention.
- One such activity in accordance with the invention is appropriate transport from the endoplasmic reticulum to the particular destination of GCase in the cell, i.e., the lysosome.
- the term "functional GCase protein” refers to a GCase protein that has the ability to fold in a proper conformation, achieve its native location in the cell, and have catabolic activity towards glucocerebroside and other lipid substrates.
- a functional GCase protein includes wild-type GCase proteins (see definitions below), e.g. , as depicted in SEQ ID NO: 2.
- mutant GCase refers to a GCase translated from a gene containing one or more genetic mutations that result in an altered protein sequence that does not achieve its native conformations under the conditions normally present in the ER. The failure to achieve this conformation results in the GCase being degraded, rather than being transported through its normal pathway in the protein transport system to its proper location within the cell.
- Some specific embodiments of such GCase mutations are the N370S mutation and the L444P mutation.
- enhancing the activity of GCase means stabilizing a proper conformation of a mutant GCase protein in the ER so that it folds in a proper conformation, achieves its native location in the cell, and has catabolic activity towards cerebroside, its lipid substrate). This term also refers to increasing the wild-type activity of an exogenously administered GCase protein, i.e. , by increasing the stability and extending the in vivo half-life of wild-type GCase, thus, prolonging its activity.
- the term "stabilize a proper conformation” refers to the ability of a compound of the invention to induce or stabilize the conformation of a mutated GCase, regardless whether in the ER or other cellular compartments, that is functionally identical to the conformation of the wild type enzyme.
- functionally identical the invention means that there may be minor variations in the conformation (indeed almost all proteins exhibit some conformational flexibility in their physiological state) but that conformational flexibility does not result in (1) aggregation, (2) elimination through the endoplasmic reticulum-associated degregation, (3) impairment of enzyme function, and/or (4) improper transport within the cell.
- wild-type GCase gene refers to nucleic acid sequences which encode an
- wild-type GCase nucleic acid sequence may contain nucleotide changes that differ from the known, published sequence, e.g. , SEQ ID NO: 1, as long as the changes result in amino acid substitutions that have little or no effect on the biological activity.
- wild-type may also include GCase nucleic acid sequences engineered to encoding a GCase protein capable of increased or enhanced activity relative to the endogenous or native GCase protein.
- a "wild-type GCase protein” refers to any protein encoded by a wild-type gene that is capable of having functional biological activity when expressed or introduced in vivo.
- isolated means that the referenced material is removed from the environment in which it is normally found.
- an isolated biological material can be free of cellular components, i.e. , components of the cells in which the material is found or produced.
- an isolated nucleic acid includes a PCR product, an isolated mRNA, a cDNA, or a restriction fragment.
- an isolated nucleic acid is preferably excised from the chromosome in which it may be found, and more preferably is no longer joined to non-regulatory, non-coding regions, or to other genes, located upstream or downstream of the gene contained by the isolated nucleic acid molecule when found in the chromosome.
- the isolated nucleic acid lacks one or more introns. Isolated nucleic acid molecules include sequences inserted into plasmids, cosmids, artificial chromosomes, and the like.
- a recombinant nucleic acid is an isolated nucleic acid.
- An isolated protein may be associated with other proteins or nucleic acids, or both, with which it associates in the cell, or with cellular membranes if it is a membrane- associated protein.
- an isolated GCase protein is a recombinant GCase protein expressed from an expression vector.
- An isolated material may be, but need not be, purified. The term "purified" as used herein refers to material that has been isolated under conditions that reduce or eliminate unrelated materials, i.e. , contaminants.
- a purified GCase protein is preferably substantially free of other proteins or nucleic acids with which GCase is normally associated in a cell.
- the term “substantially free” is used operationally, in the context of analytical testing of the material.
- purified ASM substantially free of contaminants is at least 50% pure; more preferably, at least 90% pure, and more preferably still at least 99% pure. Purity can be evaluated by chromatography, gel electrophoresis, immunoassay, composition analysis, biological assay, and other methods known in the art.
- the terms “about” and “approximately” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements.
- Typical, exemplary degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values.
- the terms “about” and “approximately” may mean values that are within an order of magnitude, preferably within 10- or 5-fold, and more preferably within 2-fold of a given value. Numerical quantities given herein are approximate unless stated otherwise, meaning that the term “about” or “approximately” can be inferred when not expressly stated.
- host cell means any cell of any organism that is selected, modified, transformed, grown, or used or manipulated in any way, for the production of a substance by the cell, for example the expression by the cell of a mutant or functional mammalian GCase gene, including a DNA or RNA sequence, or the GCase enzyme. Host cells can further be used for preliminary evaluation of the ASSC concept other assays.
- a "recombinant DNA molecule” is a DNA molecule that has undergone a molecular biological manipulation or engineering.
- a “gene” is a sequence of nucleotides which code for a "gene product” . Generally, a gene product is a protein.
- a gene product can also be another type of molecule in a cell, such as an RNA (e.g. , a tRNA or a rRNA).
- a gene product also refers to an mRNA sequence which may be found in a cell.
- a gene refers to the nucleotide sequences encoding wild-type or mutant GCase.
- RNA such as rRNA or mRNA
- a GCase protein by activating the cellular functions involved in transcription and translation of a corresponding GCase gene or DNA sequence, i.e. , sequences encoding GCase.
- a GCase DNA sequence is expressed by a cell to form an "expression product" such as a GCase RNA (e.g. , an mRNA or an rRNA) or a GCase protein.
- the expression product itself, e.g.
- the resulting GCase RNA or protein may also said to be “expressed” by the cell.
- transfection means the introduction of a foreign nucleic acid into a cell.
- transformation also means the introduction of a "foreign” (i.e. , extrinsic or extracellular) gene, DNA or RNA sequence into a host cell so that the host cell will express the introduced gene or sequence to produce a desired substance, in this invention typically an RNA coded by the introduced gene or sequence, but also a protein or an enzyme coded by the introduced gene or sequence.
- the introduced gene or sequence may also be called a "cloned” or “foreign” gene or sequence, may include regulatory or control sequences (e.g.
- a host cell that receives and expresses introduced DNA or RNA has been "transformed” and is a "transformant” or a "clone” .
- the DNA or RNA introduced to a host cell can come from any source, including cells of the same genus or species as the host cell or cells of a different genus or species.
- transfection or transformation will include introduction of sequences encoding functional GCase in individuals having mutated endogenous GCase genes.
- vector means the vehicle by which a GCase DNA or RNA sequence (e.g. , a foreign gene) can be introduced into a host cell so as to transform the host and promote expression (e.g. , transcription and translation) of the introduced sequence.
- Vectors include any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, virus, virion, etc. , which is capable of replication when associated with the proper control elements and which can transfer GCase gene sequences between cells.
- the term includes cloning and expression vehicles, as well as viral vectors.
- expression system means a host cell and compatible vector under suitable conditions, e.g.
- a GCase protein coded for by foreign DNA carried by the vector and introduced to the host cell Common expression systems include E. coli host cells and plasmid vectors, insect host cells such as S 9, Hi5 or S2 cells and Baculovirus vectors and expression systems, and mammalian host cells and vectors.
- gene therapy refers to a method of changing the expression of an endogenous gene by exogenous administration of a gene, i.e. , a GCase gene.
- gene therapy also refers to the replacement of a defective GCase gene, or replacement of a missing GCase gene, by introducing a functional gene corresponding to the defective or missing GCase gene into somatic or stem cells of an individual in need.
- Gene therapy can be accomplished by "ex vivo" methods, in which differentiated or somatic stem cells are removed from the individual's body followed by the introduction of a normal copy of the defective gene into the explanted cells using a viral vector as the gene delivery vehicle.
- in vivo direct gene transfer is gene transfer into cells in the individual in situ using a broad range of viral vectors, liposomes, protein DNA complexes, or naked DNA in order to achieve a therapeutic outcome.
- recombinant protein refers to a GCase protein (gene product) encoded by a therapeutic GCase gene carried on a vector.
- the cell receiving the vector will lack expression and/or activity of any endogenous GCase protein corresponding to the recombinant protein, or if there is expression of such an endogenous GCase protein, it is of a mutant or at a very low level.
- the recombinant protein is produced by a cell in tissue culture for experimental and therapeutic purposes.
- the recombinant protein is produced in vivo from cells transformed with vector, wherein the vector or the cells comprising the vector have been administered to a subject, i.e. , gene therapy.
- the recombinant GCase protein will likely be indistinguishable from wild- type protein in normal individuals, i.e. , individuals who are not deficient in the protein or do not have Gaucher disease.
- Therapeutic and Administration A "subject" or “patient” is a human or an animal that has developed, or is likely to develop Gaucher disease, more particularly a mammal, preferably a rodent or a primate, and most preferably a human.
- the patient is a member of the Ashkenazi Jewish population who has been diagnosed with, or who has been identified as having an increased risk of developing Gaucher disease due inherited mutations in the GCase gene.
- the term “subject” encompasses anyone in the world having, or genetically at risk of developing, Gaucher disease.
- prevention refers to the prevention of the onset of the disease, which means to prophylactically interfere with a pathological mechanism that results in the disease, e.g., Gaucher disease.
- pathological mechanism can be an increase in mutant protein folding and expression of GCase.
- treatment means to therapeutically intervene in the development of a disease in a subject showing a symptom of this disease.
- these symptoms can include but are not limited to accumulation of GCase in lysosomes, hepatosplenomegaly, psychomotor retardation, pulmonary abnormalities degeneration of bones and joints, and progressive neurodegeneration.
- therapeutically effective amount is used herein to mean an amount or dose of the GIZ or PHCA derivatives of the present invention that is sufficient to increase the level of mutant GCase expression, e.g. , to about 3-5 % , preferably by about 10%, and more preferably by about 30% of the level found in normal cells, i.e. , cells from an individual not having Gaucher disease.
- a therapeutically effective amount can ameliorate or prevent a clinically significant deficit GCase activity in the subject.
- a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the subject, e.g. , amelioration of progressive neurodegeneration in Types 2 and 3 Gaucher patients.
- pharmaceutically acceptable refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, and dizziness, when administered to a human.
- the term "pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S.
- carrier refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered.
- Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil.
- Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin.
- the ASSC is a glucoimidazole derivatives as defined in Formula I.
- the ASSC is (5R, 6R, 7S, 8S)- 5-hydroxymethyl-2-octyl-5 ,6,7 , 8-tetrahydroimidazo [ 1 ,2-a]pyridine-6 , 7 , 8-triol .
- the ASSC also can be a C-derivative (and optionally, additionally N-alkylated) of polyhydroxycyclohexyl amine having (i) all hydroxy groups on the cyclohexyl ring in the same configurations as a glucose, providing the amine is attached to the carbon corresponding the anomeric carbon of a glucose; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker. Since the C-6 position of the glucose residue is not recognized by the most of GCase and ⁇ -glucosidases (De Bruyne et al. Eur. J. Biochem. 1979; 102:257-67), the substitutes at the C-6 position can be a hydrogen, hydroxy or hydroxymethyl.
- the present invention provides a compound of the Formula I: wherein B is hydrogen, hydroxy, N-acetamino, or halogen;
- R 1 and R 2 optionally present are short, flexible linkers linear length of about 6k to about 12A, preferably about 9A.
- R 1 and R 2 can also be independently C2-C6 substituted or unsubstituted: alkyl, alkenyl, or alkynyl, which are optionally interrupted by one or more moieties chosen from the group consisting of NH, NHCOO, NHCONH, NHCSO, NHCSNH, CONH, NHCO, NR 3 , O, S, S(0) and whereas m is 1 or 2, and R 3 is independently selected from each occurrence a hydrogen, or a substituted or unsubstituted: alkyl, alkenyl; alknyl; cycloalkyl, cycloalkenyl; aryl; arylalkyl; heteroaryl; heterocyclic; heterocycly alkyl; or heteroarylalkyl, or -C(O) attached to a Ci-C ⁇ substituted or unsubstituted
- R'-L 1 or R 2 -L 2 can be a hydrogen, if R 2 -L 2 or R ⁇ L 1 is other than a hydrogen, respectively.
- R 5 represents a hydrogen, hydroxy, or hydroxymethyl. In a preferred embodiment, R 5 is hydroxymethyl.
- L 1 and L 2 are lipophilic groups having 3 - 12 carbon atoms comprising a substituted or unsubstituted: alkyl, alkenyl, alkynyl; cycloalkyl, cycloalkenyl; aryl; arylalkyl; heteroaryl; heterocyclic; heterocycloalkyl; or heteroarylalkyl.
- R ⁇ L 1 is unsubstituted C1-C12 alkyl, or more preferably an unsubstituted C ⁇ -Cn alkyl, or more preferably an unsubstituted Cs alkyl.
- R ⁇ L 1 is an unsubstituted branched C3-12 alkyl, or an unsubstituted branched C ⁇ - ⁇ alkyl, or more preferably an unsubstituted branched C ⁇ alkyl.
- R ⁇ L 1 is 3,3-dimethylbutyl.
- a preferred compound of the invention is (5R, 6R, 7S, 8S)-5-hydroxymethyl- 2-octyl-5,6,7,8-tetrahydroimidazo[ 1 ,2-a]pyridine-6,7,8-triol.
- Other preferred compounds of the invention include (5R, 6R, 7S, 8S)-5-hydroxymethyl-2-(3,3- dimethylbutyl)-5,6,7,8-tetrahydroimidazo[l,2-a]pyridine-6,7,8-triol, (5R, 6R, 7S, 8S)- 5-hydroxymethyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyridine-6,7,8-triol, and (5R, 6R, 7S, 8S)-5-hydroxymethyl-2-phenethyl-5,6,7,8-tetrahydroimidazo[l,2-a]pyridine-
- B is hydrogen, hydroxy, N-acetamino, or halogen
- R 1 is a hydrogen, substituted or unsubstituted: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heterocyclic, heterocycly alkyl, or heteroarylalkyl; -C(O)R 3 or -S(O) m R 3 ;
- R 2 optionally present is a short, flexible linker linear length of about 6A to about 12 A, preferably about 8 A - 10 A, and more preferrably about 9A.
- R 2 can aso be group having 2 - 6 carbon atoms comprising a substituted or unsubstituted: alkyl, alkenyl, or alkynyl, which are optionally interrupted by one or more moieties chosen from the group consisting of NH, NHCOO, NHCONH, NHCSO, NHCSNH, CONH, NHCO, NR 3 , O, S, S(O)m and -S(O)m NR 3 ; whereas m is 1 or 2, and R 3 is independently selected from each occurrence a hydrogen, or a substituted or unsubstituted: alkyl, alkenyl; alknyl; cycloalkyl, cycloalkenyl; aryl; arylalkyl; heteroaryl; heterocyclic; heterocycly alkyl; or heteroarylalkyl, or -C(O) attached to a G-Ce substituted or unsubstituted alkyl;and L is a lipophil
- R 2 -L can be a hydrogen.
- R 5 represents a hydrogen, hydroxy, or hydroxymethyl. In a preferred embodiment, R 5 is hydroxymethyl.
- PHCA derivatives Collectively, the compounds of Formula II are referred to as "PHCA derivatives.”
- Compounds of the present invention include pharmaceutically acceptable salts and pro-drugs of Formula I and Formula II.
- Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, Mn; salts of organic bases such as N,N'- diacetylethylenediamine, glucamine, triethylamine, choline, hydroxide, dicyclohexylamine, metformin, benzylamine, trialkylamine, thiamine; chiral bases like alkylphenylamine, glycinol, phenyl glycinol, salts of natural amino acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, omithine, lysine, arginine, serine; non-natural amino acids such as D-isomers or substituted amino acids; guanidine, substituted gu
- Salts may include acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates.
- acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates.
- solvates may be hydrates or comprise other solvents of crystallization such as alcohols.
- Prodrugs are compounds which are converted in vivo to active forms (see, e.g. , R. B. Silverman, 1992, “The Organic Chemistry of Drug Design and Drug Action", Academic Press, Chp. 8). Prodrugs can be used to alter the biodistribution (e.g. , to allow compounds which would not typically enter the reactive site of the protease) or the pharmacokinetics for a particular compound.
- a carboxylic acid group can be esterified, e.g. , with a methyl group or an ethyl group, to yield an ester.
- the ester When the ester is administered to a subject, the ester is cleaved, enzymatically or non-enzymatically, reductively, oxidatively, or hydrolytically, to reveal the anionic group.
- An anionic group can be esterified with moieties (e.g. , acyloxymethyl esters) which are cleaved to reveal an intermediate compound which subsequently decomposes to yield the active compound.
- moieties e.g. , acyloxymethyl esters
- Examples of prodrugs and their uses are well known in the art (See, e.g. , Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19).
- the prodrugs can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compound with a suitable derivatizing agent.
- hydroxy groups can be converted into esters via treatment with a carboxilic acid in the presence of a catalyst.
- cleavable alcohol prodrug moieties include substituted and unsubstituted, branched or unbranched lower alkyl ester moieties, (e.g. , ethyl esters), lower alkenyl esters, di-lower alkyl-amino lower- alkyl esters (e.g.
- R 1 and R 2 optionally present are short, flexible linkers having a linear length of about 6A to about 12A, preferably about 9A.
- R 1 and R 2 can also be independently C2-C6 substituted or unsubstituted: alkyl, alkenyl, or alkynyl, which are optionally interrupted by one or more moieties chosen from the group consisting of NH, NHCOO, NHCONH, NHCSO, NHCSNH, CONH, NHCO, NR 3 , O, S, S(O)m and -S(O)m NR 3 ; whereas m is 1 or 2, and R 3 is independently selected from each occurrence a hydrogen, or a substituted or unsubstituted: alkyl, alkenyl; alknyl; cycloalkyl, cycloalkenyl; aryl; arylalkyl; heteroaryl; heterocyclic; heterocycly alkyl; or heteroarylalkyl.
- L 1 and L 2 are lipophilic groups having 3 - 12 carbon atoms comprising a substituted or unsubstituted: alkyl, alkenyl, alkynyl; cycloalkyl, cycloalkenyl; aryl; arylalkyl; heteroaryl; heterocyclic; heterocycloalkyl; or heteroarylalkyl.
- This synthesis comprises the steps of: a) reacting a compound of the Formula IV:
- the present invention further provides a method for the prevention or treatment of Gaucher disease, which method comprises increasing the expression or activity of the mutant GCase, or by increasing or stabilizing the activity of recombinant, wild-type replacement GCase (i.e. , ERT or gene therapy), in a subject or patient in need of such treatment.
- a "therapeutically effective amount” also means an amount of the GIZ or PHCA derivative that enhances without inhibiting the activity of the GCase protein, i.e. , an effective amount enhances more than it inhibits so the net effect is an enhancement. This will generally fall somewhere below the ICso value of that inhibitor for GCase intracellular ly, or below about 50 ⁇ M in culture medium.
- the small molecule analogue that increases GCase expression or activity is advantageously formulated in a pharmaceutical composition, with a pharmaceutically acceptable carrier.
- the GIZ or PHCA derivative is the active ingredient or therapeutic agent.
- concentration or amount of the active ingredient depends on the desired dosage and administration regimen, as discussed below. Suitable dose ranges of the small molecule analogue may include from about 10 ⁇ g/kg to about 100 g/kg of body weight per day.
- the pharmaceutical compositions of the invention may also include other biologically active compounds in addition to GIZ or PHCA derivatives of the present invention.
- the small molecule may be administered in solution with the replacement, wild-type (or otherwise functional) recombinant GCase during enzyme infusion in replacement therapy.
- Protein replacement therapy increases the amount of protein by exogenously introducing wild-type or biologically functional protein by way of infusion. This therapy has been developed for many genetic disorders including Gaucher disease.
- the wild- type enzyme is purified from a recombinant cellular expression system (e.g. , mammalian cells or insect cells-see U.S. Patent Nos.
- the exogenous GCase After the infusion, the exogenous GCase is expected to be taken up by tissues through non-specific or receptor-specific mechanism. In general, the uptake efficiency is not high, and the circulation time of the exogenous protein is short. In addition, the exogenous GCase is unstable and subject to rapid intracellular degradation. Accordingly, it is expected that co-administration with the GIZ or PHCA compounds of the present invention, which act as chaperones for the enzyme, will improve the stability and prevent the degradation of the exogenously administered GCase.
- the small molecule analogue also may be administered in conjunction with, but not necessarily the same composition, as the recombinant wild-type, or otherwise functional, GCase protein.
- the replacement GCase protein and the GIZ or PHCA compounds of the present invention are formulated in separate compositions.
- the GIZ or PHCA derivatives and the replacement GCase may be administered according to the same route, e.g. , intravenous infusion, or different routes, e.g. , intravenous infusion for the replacement protein, and oral administration for the GIZ or PHCA compound.
- GIZ or PHCA Derivatives and Gene Therapy may be administered in conjunction with a recombinant vector encoding a wild-type, or otherwise functional GCase gene, i.e. , in association with gene therapy.
- recombinant gene therapy methods are in clinical or pre-clinical development for the treatment of lysosomal storage disorders, see, e.g. , U.S. Pat. No. 5,658,567, for recombinant alpha-galactosidase A therapy for Fabry disease; U.S. Pat. No.
- the GIZ or PHCA derivative will also stabilize and enhance expression of any endogenous mutant GCase that is deficient as a result of mutations that prevent proper folding and processing in the ER.
- the pharmaceutical composition of the invention e.g. , the GIZ or PHCA derivative
- Parental routes include intravenous, intra-arteriole, intramuscular, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration.
- the formulation is preferably suitable for parenteral administration, including intravenous subcutaneous, and intraperitoneal, however, formulations suitable for other routes of administration such as oral, intranasal, or transdermal are also contemplated.
- transdermal administration is achieved by liposomes. Lipid bilayer vesicles are closed, fluid-filled microscopic spheres which are formed principally from individual molecules having polar (hydrophilic) and non-polar (lipophilic) portions.
- the hydrophilic portions may comprise phosphato, glycerylphosphato, carboxy, sulfato, amino, hydroxy, choline or other polar groups.
- lipophilic groups are saturated or unsaturated hydrocarbons such as alkyl, alkenyl or other lipid groups.
- Sterols e.g. , cholesterol
- other pharmaceutically acceptable adjuvants including anti-oxidants such as alpha- tocopherol
- Liposomes are a subset of these bilayer vesicles and are comprised principally of phospholipid molecules that contain two hydrophobic tails consisting of fatty acid chains.
- each side of the membrane presents a hydrophilic surface while the interior of the membrane comprises a lipophilic medium.
- MLV multilamellar vesicles
- UV Unilamellar Vesicles
- the pharmaceutical formulations suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and polyethylene glycol), suitable mixtures thereof, and vegetable oils.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, and sorbic acid. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monosterate and gelatin.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
- the formulation contains an excipient.
- buffers such as citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer, amino acids, urea, alcohols, ascorbic acid, phospholipids; proteins, such as serum albumin, collagen, and gelatin; salts such as EDTA or EGTA, and sodium chloride; liposomes; polyvinylpyrollidone; sugars, such as dextran, mannitol, sorbitol, and glycerol; propylene glycol and polyethylene glycol (e.g. , PEG-4000, PEG-6000); glycerol; glycine or other amino acids; and lipids.
- buffers such as citrate buffer, phosphate buffer, acetate buffer, and bicarbonate buffer, amino acids, urea, alcohols, ascorbic acid, phospholipids
- proteins such as serum albumin, collagen, and gelatin
- salts such as EDTA or EGTA, and sodium chloride
- liposomes polyvinylpyrollidon
- Buffer systems for use with the formulations include citrate; acetate; bicarbonate; and phosphate buffers. Phosphate buffer is a preferred embodiment.
- the formulation also preferably contains a non-ionic detergent.
- Preferred non-ionic detergents include Polysorbate 20, Polysorbate 80, Triton X-100, Triton X-114, Nonidet P-40, octyl ⁇ -glucoside, octyl /3-glucoside, Brij 35, Pluronic, and Tween 20.
- the enzyme concentration can be 0.1-10 mg/mL.
- Bulking agents such as glycine, mannitol, albumin, and dextran
- cryoprotectants such as disaccharides, amino acids, and PEG
- Formulations of GIZ or PHCA compound (with or without the GCase) for inhalation administration may contain lactose or other excipients, or may be aqueous solutions which may contain ⁇ olyoxyethylene-9-lauryl ether, glycocholate or deoxycocholate.
- a preferred inhalation aerosol is characterized by having particles of small mass density and large size.
- Particles with mass densities less than 0.4 gram per cubic centimeter and mean diameters exceeding 5 ⁇ m efficiently deliver inhaled therapeutics into the systemic circulation. Such particles are inspired deep into the lungs and escape the lungs' natural clearance mechanisms until the inhaled particles deliver their therapeutic payload (Edwards et al. , Science 1997; 276: 1868- 1872).
- Replacement protein preparations of the present invention can be administered in aerosolized form, for example by using methods of preparation and formulations as described in, U.S. Pat. Nos. 5,654,007, 5,780,014, and 5,814,607, each incorporated herein by reference.
- Formulation for intranasal administration may include oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
- Formulations for topical administration to the skin surface may be prepared by dispersing the composition with a dermatological acceptable carrier such as a lotion, cream, ointment, or soap. Particularly useful are carriers capable of forming a film or layer over the skin to localize application and inhibit removal.
- a dermatological acceptable carrier such as a lotion, cream, ointment, or soap.
- Particularly useful are carriers capable of forming a film or layer over the skin to localize application and inhibit removal.
- the composition may be dispersed in a liquid tissue adhesive or other substance known to enhance adsorption to a tissue surface.
- tissue-coating solutions such as pectin-containing formulations may be used.
- the formulations of the invention are supplied in either liquid or powdered formulations in devices which conveniently administer a predetermined dose of the preparation; examples of such devices include a needle- less injector for either subcutaneous or intramuscular injection, and a metered aerosol delivery device.
- the preparation may be supplied in a form suitable for sustained release, such as in a patch or dressing to be applied to the skin for transdermal administration, or via erodable devices for transmucosal administration.
- the formulation e.g. , the GIZ or PHCA is orally administered in tablet or capsule form
- the preparation might be supplied in a bottle with a removable cover or as blister patches.
- the compound in the embodiment where the GIZ or PHCA derivative is administered separately than the GCase (or a vector comprising a GCase gene), is administered alone as monotherapy, the compound can be in a form suitable for any route of administration, including but not limited to all of the forms described above.
- the small molecule analogue can be formulated for oral administration in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. , pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. , lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. , magnesium stearate, talc or silica); disintegrants (e.g. , potato starch or sodium starch glycolate); or wetting agents
- binding agents e.g. , pregelatinized maize starch, polyvinylpyrrolidone or
- Liquid preparations for oral administration of GIZ or PHCA derivative may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. , sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. , lecithin or acacia); non-aqueous vehicles (e.g.
- the preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- the small molecule analogue may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. , containing conventional suppository bases such as cocoa butter or other glycerides.
- the GIZ or PHCA derivative may also be formulated as a depot preparation.
- Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the GIZ or PHCA derivative may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. Timing.
- administration may be simultaneous, or the GIZ or PHCA derivative may be administered prior to, or after the GCase replacement protein.
- the GIZ or PHCA derivative may be administered during a period from 0 h to 6 h later.
- the GIZ or PHCA derivative may be administered from 0 to 6 h prior to the protein.
- the GIZ or PHCA derivative and replacement protein are administered separately, and where the has a short circulating half-life (e.g. , small molecule)
- the GIZ or PHCA derivative may be orally administered continuously, such as daily, in order to maintain a constant level in the circulation.
- Such constant level will be one that has been determined to be non-toxic to the patient, and optimal regarding interaction with a target replacement protein during the time of administration to confer a non-inhibitory, therapeutic effect.
- the GIZ or PHCA derivative is administered during the time period required for turnover of the replacement GCase protein (which will be extended by administration of the small molecule analogue). Regardless of the timing, the administration must be such that the concentrations of the GCase and GIZ or PHCA derivative must be such that the small molecule stabilizes, but does not prevent or inhibit the protein's activity in vivo. This also applies where the replacement protein and small molecule are administered in the same formulation. With respect to the timing of the GIZ or PHCA derivative and gene therapy combination therapy, administration of the small molecule according to the present invention will generally follow delivery of the GCase gene, to allow for expression of the recombinant enzyme by the target cells/tissue.
- the GIZ or PHCA derivative Since the expression of the GCase gene will be sustained for a period of time, for as long as the gene is expressible, the GIZ or PHCA derivative will be remained effective as a chaperone and stabilizer for the recombinant enzyme. Therefore, administration of the chaperone molecule will be necessary for the same period as the gene is expressed.
- the GIZ or PHCA derivative since the GIZ or PHCA derivative may have a short circulating half-life, it is preferred that it will be orally administered frequently, such as daily, in order to maintain a constant level in the circulation. Such a constant level will be one that has been determined to be non-toxic to the patient, and optimal regarding interaction with the protein, which will be continuously produced, to confer a non-inhibitory, therapeutic effect.
- the timing of the small molecule analogue delivery becomes less significant since the effective amount can enhance the activity of the endogenous mutant GCase as well as increase the efficiency of the therapeutic GCase gene product.
- the presence of an small molecule chaperone, e.g. , the GIZ or PHCA derivatives of the present invention, for the GCase encoded by the administered GCase gene will have the benefit of improving the efficiency of protein processing during synthesis in the ER (i.e.
- the amount of the GIZ or PHCA compound effective to stabilize the administered GCase protein and/or endogenous GCase mutant protein can be determined by those skilled in the art. Pharmacokinetics and pharmacodynamics such as half-life (tin), peak plasma concentration (Cmax), time to peak plasma concentration (W), exposure as measured by area under the curve (AUC), and tissue distribution for both the replacement GCase protein and the small molecule analogue as well as data for the small molecule analogue-replacement GCase protein binding (affinity constants, association and dissociation constants, and valency), can be obtained using ordinary methods known in the art to determine compatible amounts required to stabilize the replacement GCase protein, without inhibiting its activity, and thus confer a therapeutic effect.
- tin half-life
- Cmax peak plasma concentration
- W time to peak plasma concentration
- AUC area under the curve
- tissue distribution for both the replacement GCase protein and the small molecule analogue as well as data for the small
- Toxicity and therapeutic efficacy of the composition can be determined by standard pharmaceutical procedures, for example in cell culture assays or using experimental animals to determine the LD50 and the EDso.
- the parameters LDso and EDso are well known in the art, and refer to the doses of a compound that is lethal to 50% of a population and therapeutically effective in 50% of a population, respectively.
- the dose ratio between toxic and therapeutic effects is referred to as the therapeutic index and may be expressed as the ratio: LD50/ED50.
- a therapeutically effective dose may be initially estimated from cell culture assays and formulated in animal models to achieve a circulating concentration range that includes the IC50.
- the IC50 concentration of a compound is the concentration that achieves a half-maximal inhibition of symptoms (e.g.
- the concentration of replacement GCase protein is between 0.05-5.0 mg/kg of body weight, typically administered weekly or biweekly.
- the protein can be administered at a dosage ranging from 0.1 ⁇ g/kg to about 10 mg/kg, preferably from about 0.1 mg/kg to about 2 mg/kg. Regularly repeated doses of the protein are necessary over the life of the patient. Subcutaneous injections maintain longer term systemic exposure to the drug.
- the GCase is preferably administered intravenously, e.g. , in an intravenous bolus injection, in a slow push intravenous injection, or by continuous intravenous injection. Continuous IV infusion (e.g. , over 2-6 hours) allows the maintenance of specific levels in the blood.
- the optimal concentrations of the GIZ or PHCA derivative will be determined according to the amount required to stabilize the recombinant GCase protein in vivo, in tissue or circulation, without preventing its activity, bioavailability of the small molecule analogue in tissue or in circulation, and metabolism of the small molecule analogue in tissue or in circulation.
- the concentration of the 2-Octyl GIZ may be determined by calculating the ICso value of the 2-Octyl GIZ for GCase. Taking into consideration bioavailability and metabolism of the compound, concentrations around the ICso value or slightly over the ICso value can then be evaluated based on effects on GCase activity, e.g. , the amount of small molecule analogue needed to increase the amount of GCase activity or prolong activity of replacement GCase.
- EXAMPLE 1 Synthesis of GIZ derivatives a. (5R, 6R, 7S, 8S)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-2-(l-octynyl)- 5,6,7,8-tetrahydroimidazo[l,2-a]pyridine (5R, 6R, 7S, 8S)-6,7,8-Tris(benzyloxy)-5-[(benzyloxy)methyl]-2-iodo-
- EXAMPLE 2 Inhibitory Activities of Glucoimidazole Derivatives Against GCase.
- the enzyme activity was assayed with 4-methylumbelliferyl ⁇ - glucoside (final concentration 3 mM) as substrate in Reaction Buffer consisting 0.25% sodium taurocholate, 0.1% Triton X-100 in Mcllvaine buffer (0.1M citrate and 0.2M phosphate buffer) at pH 5.2.
- the compounds were added to each reaction mixture individually at the final concentration indicated.
- the reaction was stopped by addition of 0.2 M glycine buffer, pH 10.8, the released 4-methylumbelliferone was determined by a fluoremeter at excitation wavelength of 355 nm and emission wavelength at 460 nm, respectively.
- Fibroblasts established from Gaucher patients with N370S/N370S mutation were cultured in DMEM medium supplemented with 10% fetal bovine serum and antibiotics at 37°C under 5% CO2.
- the GIZ was added into the culture medium at the final concentrations for 4 days prior to the assay.
- the cells were harvested and homogenized in the presence of 0.25 % (w/v) sodium taurocholate and 0.1 % (v/v) Triton X-100 in Mcllvaine buffer (pH 5.2, Reaction Buffer), and 10 ⁇ l of the lysate was used for the determination of residual enzyme activity.
- the activity of the GCase was determined with 3 mM 4-MU- ⁇ -Glc in the Reaction Buffer at 37°C for 1 hr as conduritol B epoxide (CBE)-sensitive activity in parallel assays without or with pre- incubation with CBE at 1.25 mM for 30 min at room temperature. Protein concentrations in the cell lysates were determined using micro BCA protein assay kit from Pierce. Results. In order to examine the ability of the novel compounds to rescue mutant enzyme activity from degradation in the ER, GIZ was added at various concentrations in the culture medium of fibroblasts established from Gaucher patient with homozygous N370S mutation. The residual enzyme activity in patient cells cultivated with inhibitors were shown to be increased approximately 2-fold.
- the optimal concentration for the maximum enhancement was approximately at 300 ⁇ M. Incubation of the cells with GIZ at higher concentrations results in the reduction of the residual enzyme activity, presumably caused by inhibition of GIZ at those concentrations. It has been indicated that optimal concentration for chaperone activity is dependent on the potency of inhibitory activity and the bioavailability (Fan et al., Trends Pharmacol Sci. 2003; 24:355-60). The combination of the highest inhibitory activity and good permeability may contribute the lower optimal concentration as a chaperone for the GCase activity in Gaucher disease.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0416216-1A BRPI0416216A (en) | 2003-11-12 | 2004-11-12 | glycoimidazole and polyhydroxycyclohexenyl compound and method for synthesizing glycoimidazole and polyhydroxycyclohexenyl compound, methods for inhibiting glucocerebrosidase, for enhancing glucocerebrosidase activity, pharmaceutical composition, methods for inhibiting a -glycosity, and for treating gaucher disease, glycoimidazole and polyhydroxycyclohexylamine derivatives |
AU2004289327A AU2004289327A1 (en) | 2003-11-12 | 2004-11-12 | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat Gaucher disease |
CA002545433A CA2545433A1 (en) | 2003-11-12 | 2004-11-12 | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
JP2006539869A JP2007510753A (en) | 2003-11-12 | 2004-11-12 | Glucoimidazole derivatives and polyhydroxycyclohexenylamine derivatives for the treatment of Gaucher disease |
EP04810771A EP1682134A4 (en) | 2003-11-12 | 2004-11-12 | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
IL175472A IL175472A0 (en) | 2003-11-12 | 2006-05-07 | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51949603P | 2003-11-12 | 2003-11-12 | |
US60/519,496 | 2003-11-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005046611A2 true WO2005046611A2 (en) | 2005-05-26 |
WO2005046611A3 WO2005046611A3 (en) | 2005-09-09 |
Family
ID=34590422
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/037703 WO2005046611A2 (en) | 2003-11-12 | 2004-11-12 | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
PCT/US2004/037704 WO2005046612A2 (en) | 2003-11-12 | 2004-11-12 | Hydroxy piperidine derivatives to treat gaucher disease |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/037704 WO2005046612A2 (en) | 2003-11-12 | 2004-11-12 | Hydroxy piperidine derivatives to treat gaucher disease |
Country Status (10)
Country | Link |
---|---|
US (3) | US20050137223A1 (en) |
EP (2) | EP1682504B1 (en) |
JP (2) | JP4767172B2 (en) |
CN (2) | CN1906162B (en) |
AU (2) | AU2004289327A1 (en) |
BR (2) | BRPI0416216A (en) |
CA (2) | CA2545433A1 (en) |
ES (1) | ES2402182T3 (en) |
IL (2) | IL175444A (en) |
WO (2) | WO2005046611A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1888068A2 (en) * | 2005-06-08 | 2008-02-20 | Amicus Therapeutics, Inc. | Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes |
WO2008059267A1 (en) * | 2006-11-15 | 2008-05-22 | The University Court Of The University Of Dundee | Selective glycosidase inhibitors |
EP2139323A1 (en) * | 2007-04-13 | 2010-01-06 | Amicus Therapeutics, Inc. | Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
US7829579B2 (en) | 2006-06-23 | 2010-11-09 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase |
WO2013079580A1 (en) | 2011-11-29 | 2013-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of darier disease |
WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US9353117B2 (en) | 2010-12-08 | 2016-05-31 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
US10570135B2 (en) | 2014-11-06 | 2020-02-25 | Lysosomal Therapeutics Inc. | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders |
US10786508B2 (en) | 2014-11-06 | 2020-09-29 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US10934298B2 (en) | 2016-04-06 | 2021-03-02 | BIAL—BioTech Investments, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11168087B2 (en) | 2016-05-05 | 2021-11-09 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7842470B2 (en) * | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
FR2887549B1 (en) * | 2005-06-23 | 2009-07-10 | Centre Nat Rech Scient | NOVEL COMPOUNDS OF THE FAMILY OF IMINOSUCRES, THEIR USES, IN PARTICULAR FOR THE TREATMENT OF LYSOSOMAL DISEASES, AND THEIR PROCESS OF PREPARATION |
PL2787345T3 (en) | 2006-05-16 | 2016-08-31 | Amicus Therapeutics Inc | Treatment options for fabry disease |
US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
KR101650726B1 (en) | 2007-05-22 | 2016-08-24 | 아미쿠스 세라퓨틱스, 인코포레이티드 | New method for preparing isofagomine and its derivatives |
EP2416656B1 (en) * | 2009-04-09 | 2015-12-23 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating lysosomal storage disorders |
WO2012139748A1 (en) | 2011-04-11 | 2012-10-18 | Roche Diagnostics Gmbh | Dna polymerases with improved activity |
CN103635230B (en) | 2011-05-12 | 2017-10-31 | 普罗蒂斯特斯治疗公司 | Albumen homeostasis conditioning agent |
WO2013112651A2 (en) | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
WO2013148103A1 (en) * | 2012-03-27 | 2013-10-03 | Amicus Therapeutics, Inc. | Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system |
US20150118221A1 (en) * | 2012-05-08 | 2015-04-30 | The John Hopkins University | Compositions and methods for treating cardiac hypertrophy |
JP2017502961A (en) * | 2013-12-23 | 2017-01-26 | アレクトス セラピューティックス インコーポレイテッド | Glucocerebrosidase modulator and use thereof |
EP3264092A1 (en) * | 2016-07-01 | 2018-01-03 | Centogene AG | Use of lyso-gb1 as druggable target |
EP3501495A1 (en) | 2017-12-21 | 2019-06-26 | InnoMedica Holding AG | Liposomes comprising sphingomyelin |
EP3814338A1 (en) | 2018-06-27 | 2021-05-05 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
EP3814336A1 (en) | 2018-06-27 | 2021-05-05 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3105833A (en) * | 1962-04-03 | 1963-10-01 | Grace W R & Co | 4, 5-dihydroxy-piperidazines and their production |
DE2848117A1 (en) * | 1978-11-06 | 1980-05-14 | Bayer Ag | DERIVATIVES OF 2-HYDROXYMETHYL-3,4,5-TRIHYDROXY-PIPERIDINE, THEIR PRODUCTION AND USE THEREFORE INFLUENCING THE CARBOHYDRATE AND FATTY METHODOLOGY |
DE3737523A1 (en) * | 1987-11-05 | 1989-05-18 | Bayer Ag | USE OF SUBSTITUTED HYDROXYPIPERIDINES AS ANTIVIRAL AGENTS |
US5179023A (en) * | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
US6291657B1 (en) * | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
JP3561546B2 (en) * | 1995-01-06 | 2004-09-02 | 四国化成工業株式会社 | New 5,6,7,8-tetrahydro-imidazo [1,2-a] pyridine compounds |
US5962313A (en) * | 1996-01-18 | 1999-10-05 | Avigen, Inc. | Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme |
WO1997031901A1 (en) * | 1996-02-29 | 1997-09-04 | Mikael Bols | Hydroxyhexahydropyridazines |
CA2260790C (en) * | 1996-07-15 | 2007-01-09 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
US6083725A (en) * | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
EP1027069B1 (en) * | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
ATE234626T1 (en) * | 1999-07-26 | 2003-04-15 | Searle & Co | USE OF LONG CHAIN N-ALKYL DERIVATIVES OF DEOXYNOJIRIMYCIN WITH GLUCOCEREBROSIDASE ENZYMES FOR PRODUCING A MEDICATION FOR THE TREATMENT OF DISEASES RELATED TO GLYCOLIPID ACCUMULATION |
US7138262B1 (en) * | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
WO2004037373A2 (en) | 2002-10-21 | 2004-05-06 | The Scripps Research Institute | CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF β-GLUCOSIDASE |
-
2004
- 2004-11-12 EP EP04810772A patent/EP1682504B1/en active Active
- 2004-11-12 AU AU2004289327A patent/AU2004289327A1/en not_active Abandoned
- 2004-11-12 US US10/988,427 patent/US20050137223A1/en not_active Abandoned
- 2004-11-12 CN CN2004800402432A patent/CN1906162B/en not_active Expired - Fee Related
- 2004-11-12 CA CA002545433A patent/CA2545433A1/en not_active Abandoned
- 2004-11-12 BR BRPI0416216-1A patent/BRPI0416216A/en not_active IP Right Cessation
- 2004-11-12 JP JP2006539870A patent/JP4767172B2/en not_active Expired - Fee Related
- 2004-11-12 CA CA2545435A patent/CA2545435C/en not_active Expired - Fee Related
- 2004-11-12 CN CNA2004800402413A patent/CN1901907A/en active Pending
- 2004-11-12 BR BRPI0416217A patent/BRPI0416217A8/en not_active Application Discontinuation
- 2004-11-12 AU AU2004289328A patent/AU2004289328B2/en not_active Ceased
- 2004-11-12 ES ES04810772T patent/ES2402182T3/en active Active
- 2004-11-12 WO PCT/US2004/037703 patent/WO2005046611A2/en active Application Filing
- 2004-11-12 JP JP2006539869A patent/JP2007510753A/en active Pending
- 2004-11-12 WO PCT/US2004/037704 patent/WO2005046612A2/en active Application Filing
- 2004-11-12 US US10/988,428 patent/US7741340B2/en active Active
- 2004-11-12 EP EP04810771A patent/EP1682134A4/en not_active Withdrawn
-
2006
- 2006-05-04 IL IL175444A patent/IL175444A/en active IP Right Grant
- 2006-05-07 IL IL175472A patent/IL175472A0/en unknown
-
2010
- 2010-04-08 US US12/756,382 patent/US20100189708A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of EP1682134A4 * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013079246A (en) * | 2005-06-08 | 2013-05-02 | Amicus Therapeutics Inc | Treatment of cns disorder related to mutation of gene for encoding lysosomal enzyme |
JP2009509913A (en) * | 2005-06-08 | 2009-03-12 | アミカス セラピューティックス インコーポレイテッド | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
EP1888068A4 (en) * | 2005-06-08 | 2009-12-09 | Amicus Therapeutics Inc | Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes |
US7964617B2 (en) | 2005-06-08 | 2011-06-21 | Amicus Therapeutics, Inc. | Methods for treating parkinsons disease and parkinsonism |
US9597324B2 (en) | 2005-06-08 | 2017-03-21 | Amicus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
EP1888068A2 (en) * | 2005-06-08 | 2008-02-20 | Amicus Therapeutics, Inc. | Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes |
US8883813B2 (en) | 2005-06-08 | 2014-11-11 | Amacus Therapeutics, Inc. | Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
US9119845B2 (en) | 2006-06-23 | 2015-09-01 | Amicus Therapeautics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase |
US7829579B2 (en) | 2006-06-23 | 2010-11-09 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase |
US9402837B2 (en) | 2006-06-23 | 2016-08-02 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase |
US10064851B2 (en) | 2006-06-23 | 2018-09-04 | Amicus Therapeutics, Inc. | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase |
WO2008059267A1 (en) * | 2006-11-15 | 2008-05-22 | The University Court Of The University Of Dundee | Selective glycosidase inhibitors |
EP2139323A1 (en) * | 2007-04-13 | 2010-01-06 | Amicus Therapeutics, Inc. | Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
US8399525B2 (en) | 2007-04-13 | 2013-03-19 | Amicus Therapeutics, Inc. | Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
EP2139323A4 (en) * | 2007-04-13 | 2010-04-21 | Amicus Therapeutics Inc | Treatment of gaucher disease with specific pharmacological chaperones and monitoring treatment using surrogate markers |
US9974789B2 (en) | 2010-12-08 | 2018-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
US10925874B2 (en) | 2010-12-08 | 2021-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
US9353117B2 (en) | 2010-12-08 | 2016-05-31 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Substituted pyrazolopyrimidines as glucocerebrosidase activators |
WO2013079580A1 (en) | 2011-11-29 | 2013-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of darier disease |
US11351173B2 (en) | 2014-11-06 | 2022-06-07 | Bial—R&D Investments, S.A. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US10570135B2 (en) | 2014-11-06 | 2020-02-25 | Lysosomal Therapeutics Inc. | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders |
AU2015342883B2 (en) * | 2014-11-06 | 2020-07-02 | Bial - R&D Investments, S.A. | Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders |
US10751341B2 (en) | 2014-11-06 | 2020-08-25 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US10786508B2 (en) | 2014-11-06 | 2020-09-29 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders |
US11932645B2 (en) | 2014-11-06 | 2024-03-19 | Bial—R & D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
WO2016073891A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
EP3215509A4 (en) * | 2014-11-06 | 2018-03-14 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US11091492B2 (en) | 2014-11-06 | 2021-08-17 | Bial—R&D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US11400095B2 (en) | 2014-11-06 | 2022-08-02 | Bial—R&D Investments, S.A. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US10934298B2 (en) | 2016-04-06 | 2021-03-02 | BIAL—BioTech Investments, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
US11192892B2 (en) | 2016-04-06 | 2021-12-07 | Bial—R&D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11453675B2 (en) | 2016-04-06 | 2022-09-27 | Bial—R&D Investments, S.A. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
US11168087B2 (en) | 2016-05-05 | 2021-11-09 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
US11878979B2 (en) | 2016-05-05 | 2024-01-23 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
Also Published As
Publication number | Publication date |
---|---|
EP1682134A2 (en) | 2006-07-26 |
IL175444A (en) | 2013-05-30 |
EP1682504A4 (en) | 2008-10-22 |
JP4767172B2 (en) | 2011-09-07 |
IL175444A0 (en) | 2006-09-05 |
BRPI0416216A (en) | 2006-12-26 |
CN1906162A (en) | 2007-01-31 |
AU2004289327A1 (en) | 2005-05-26 |
ES2402182T3 (en) | 2013-04-29 |
CA2545433A1 (en) | 2005-05-26 |
JP2007510753A (en) | 2007-04-26 |
AU2004289328A1 (en) | 2005-05-26 |
IL175472A0 (en) | 2006-09-05 |
US20050130972A1 (en) | 2005-06-16 |
EP1682504B1 (en) | 2012-12-26 |
AU2004289328B2 (en) | 2011-05-19 |
CN1906162B (en) | 2012-05-23 |
US7741340B2 (en) | 2010-06-22 |
WO2005046612A3 (en) | 2005-07-14 |
JP2007512253A (en) | 2007-05-17 |
CA2545435A1 (en) | 2005-05-26 |
BRPI0416217A8 (en) | 2018-05-08 |
US20050137223A1 (en) | 2005-06-23 |
US20100189708A1 (en) | 2010-07-29 |
WO2005046611A3 (en) | 2005-09-09 |
CA2545435C (en) | 2014-08-19 |
EP1682134A4 (en) | 2008-10-15 |
BRPI0416217A (en) | 2007-01-02 |
CN1901907A (en) | 2007-01-24 |
WO2005046612A2 (en) | 2005-05-26 |
EP1682504A2 (en) | 2006-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050137223A1 (en) | Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease | |
ES2705335T3 (en) | A method for the treatment of Pompe disease using 1-deoxynojirimycin and derivatives | |
US10064851B2 (en) | Method for the treatment of neurological disorders by enhancing the activity of β-glucocerebrosidase | |
KR101848938B1 (en) | NOVEL COMPOSITioNS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DisORDERS | |
ES2564093T3 (en) | Methods to prevent and / or treat lysosomal storage disorders | |
EP4201403A1 (en) | Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 175472 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2545433 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006539869 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004810771 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2964/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004289327 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004289327 Country of ref document: AU Date of ref document: 20041112 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004289327 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480040241.3 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004810771 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0416216 Country of ref document: BR |